Literature DB >> 22062970

Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3.

Livia Pisciotta1, Elda Favari, Lucia Magnolo, Sara Simonelli, Maria Pia Adorni, Raffaella Sallo, Tatiana Fancello, Ivana Zavaroni, Diego Ardigò, Franco Bernini, Laura Calabresi, Guido Franceschini, Patrizia Tarugi, Sebastiano Calandra, Stefano Bertolini.   

Abstract

BACKGROUND: Angiopoietin-like protein 3 (ANGPTL3) affects lipid metabolism by inhibiting the activity of lipoprotein and endothelial lipases. Angptl3 knockout mice have marked hypolipidemia, and heterozygous carriers of ANGPLT3, loss-of-function mutations were found among individuals in the lowest quartile of plasma triglycerides in population studies. Recently, 4 related individuals with primary hypolipidemia were found to be compound heterozygotes for ANGPTL3 loss-of-function mutations. METHODS AND
RESULTS: We resequenced ANGPTL3 in 4 members of 3 kindreds originally identified for very low levels of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol (0.97±0.16 and 0.56±0.20 mmol/L, respectively) in whom no mutations of known candidate genes for monogenic hypobetalipoproteinemia and hypoalphalipoproteinemia had been detected. These subjects were found to be homozygous or compound heterozygous for ANGPTL3 loss-of-function mutations (p.G400VfsX5, p.I19LfsX22/p.N147X) associated with the absence of ANGPTL3 in plasma. They had reduced plasma levels of triglyceride-containing lipoproteins and of HDL particles that contained only apolipoprotein A-I and pre-β-high-density lipoprotein. In addition, their apolipoprotein B-depleted sera had a reduced capacity to promote cell cholesterol efflux through the various pathways (ABCA1-, SR-BI-, and ABCG1-mediated efflux); however, these subjects had no clinical evidence of accelerated atherosclerosis. Heterozygous carriers of the ANGPTL3 mutations had low plasma ANGPTL3 and moderately reduced low-density lipoprotein cholesterol (2.52±0.38 mmol/L) but normal plasma high-density lipoprotein cholesterol.
CONCLUSIONS: Complete ANGPTL3 deficiency caused by loss-of-function mutations of ANGPTL3 is associated with a recessive hypolipidemia characterized by a reduction of apolipoprotein B and apolipoprotein A-I-containing lipoproteins, changes in subclasses of high-density lipoprotein, and reduced cholesterol efflux potential of serum. Partial ANGPTL3 deficiency is associated only with a moderate reduction of low-density lipoprotein.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22062970     DOI: 10.1161/CIRCGENETICS.111.960674

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN: 1942-3268


  40 in total

1.  Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins.

Authors:  Sergio Fazio; Jessica Minnier; Michael D Shapiro; Sotirios Tsimikas; Patrizia Tarugi; Maurizio R Averna; Marcello Arca; Hagai Tavori
Journal:  J Clin Endocrinol Metab       Date:  2017-09-01       Impact factor: 5.958

Review 2.  Hypobetalipoproteinemia and abetalipoproteinemia.

Authors:  Francine K Welty
Journal:  Curr Opin Lipidol       Date:  2014-06       Impact factor: 4.776

3.  Functional variants of lipid level modifier MLXIPL, GCKR, GALNT2, CILP2, ANGPTL3 and TRIB1 genes in healthy Roma and Hungarian populations.

Authors:  Katalin Sumegi; Luca Jaromi; Lili Magyari; Erzsebet Kovesdi; Balazs Duga; Renata Szalai; Anita Maasz; Petra Matyas; Ingrid Janicsek; Bela Melegh
Journal:  Pathol Oncol Res       Date:  2015-01-09       Impact factor: 3.201

4.  ABCA1-dependent serum cholesterol efflux capacity inversely correlates with pulse wave velocity in healthy subjects.

Authors:  Elda Favari; Nicoletta Ronda; Maria Pia Adorni; Francesca Zimetti; Paolo Salvi; Matteo Manfredini; Franco Bernini; Claudio Borghi; Arrigo F G Cicero
Journal:  J Lipid Res       Date:  2012-10-28       Impact factor: 5.922

5.  Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis.

Authors:  Ilenia Minicocci; Sara Santini; Vito Cantisani; Nathan Stitziel; Sekar Kathiresan; Juan Antonio Arroyo; Gertrudis Martí; Livia Pisciotta; Davide Noto; Angelo B Cefalù; Marianna Maranghi; Giancarlo Labbadia; Giovanni Pigna; Fabio Pannozzo; Fabrizio Ceci; Ester Ciociola; Stefano Bertolini; Sebastiano Calandra; Patrizia Tarugi; Maurizio Averna; Marcello Arca
Journal:  J Lipid Res       Date:  2013-09-20       Impact factor: 5.922

6.  Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.

Authors:  Frederick E Dewey; Viktoria Gusarova; Richard L Dunbar; Colm O'Dushlaine; Claudia Schurmann; Omri Gottesman; Shane McCarthy; Cristopher V Van Hout; Shannon Bruse; Hayes M Dansky; Joseph B Leader; Michael F Murray; Marylyn D Ritchie; H Lester Kirchner; Lukas Habegger; Alex Lopez; John Penn; An Zhao; Weiping Shao; Neil Stahl; Andrew J Murphy; Sara Hamon; Aurelie Bouzelmat; Rick Zhang; Brad Shumel; Robert Pordy; Daniel Gipe; Gary A Herman; Wayne H H Sheu; I-Te Lee; Kae-Woei Liang; Xiuqing Guo; Jerome I Rotter; Yii-Der I Chen; William E Kraus; Svati H Shah; Scott Damrauer; Aeron Small; Daniel J Rader; Anders Berg Wulff; Børge G Nordestgaard; Anne Tybjærg-Hansen; Anita M van den Hoek; Hans M G Princen; David H Ledbetter; David J Carey; John D Overton; Jeffrey G Reid; William J Sasiela; Poulabi Banerjee; Alan R Shuldiner; Ingrid B Borecki; Tanya M Teslovich; George D Yancopoulos; Scott J Mellis; Jesper Gromada; Aris Baras
Journal:  N Engl J Med       Date:  2017-05-24       Impact factor: 91.245

7.  Cholesterol efflux capacity does not associate with coronary calcium, plaque vulnerability, and telomere length in healthy octogenarians.

Authors:  Francesca Zimetti; Wladimir M Freitas; Alessandra M Campos; Mauricio Daher; Maria Pia Adorni; Franco Bernini; Andrei C Sposito; Ilaria Zanotti
Journal:  J Lipid Res       Date:  2018-02-07       Impact factor: 5.922

8.  Angiopoietin-like proteins as therapeutic targets for cardiovascular disease: focus on lipid disorders.

Authors:  Marco Bruno Morelli; Christopher Chavez; Gaetano Santulli
Journal:  Expert Opin Ther Targets       Date:  2020-01-15       Impact factor: 6.902

9.  ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys.

Authors:  Viktoria Gusarova; Corey A Alexa; Yan Wang; Ashique Rafique; Jee Hae Kim; David Buckler; Ivory J Mintah; Lisa M Shihanian; Jonathan C Cohen; Helen H Hobbs; Yurong Xin; David M Valenzuela; Andrew J Murphy; George D Yancopoulos; Jesper Gromada
Journal:  J Lipid Res       Date:  2015-05-11       Impact factor: 5.922

10.  Genetics of non-conventional lipoprotein fractions.

Authors:  Alexis C Frazier-Wood
Journal:  Curr Genet Med Rep       Date:  2015-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.